×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Nova Mentis Welcomes New Board Member - TipRanks.com
Tipranks
Nova Mentis Life Science Corp., a Canadian biotech leader in neuroinflammatory diagnostics and therapeutics, has announced the addition of...
2 months ago
Screening underway for fragile X patients in psilocybin microdose...
Fragile X News Today
Screening of potential participants has begun in a Phase 2a trial that will test Nova Mentis Life Science's NM-1001, a microdose of the...
8 months ago
NEXT SUPER STOCK Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) Psilocybin Autism Phase 2A Clinical ...
Wall Street Reporter
NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) is developing treatment for autism based on psilocybin with fast track...
15 months ago
KGK Science, Nova Mentis Cleared for Psilocybin Clinical Trial to Treat Fragile X Syndrome
Inside Precision Medicine
KGK Science will begin with its partner Nova Mentis Life Science a clinical trial assessing psilocybin as a therapy for fragile X syndrome.
14 months ago
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
Psychedelic Alpha
VANCOUVER, BC, Oct. 26, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”)…
22 months ago
Nova Mentis starts Phase II trial of psilocybin in fragile X syndrome
Clinical Trials Arena
Nova Mentis will test microdoses of psilocybin in 10 patients with fragile X syndrome, the leading cause of autism spectrum disorder.
12 months ago
UCF-BioTech Partnership Helps to Improve Autism Treatment
University of Central Florida
Through a new noninvasive diagnostic technology that uses saliva, healthcare providers will be able to better understand the patients'...
22 months ago
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
PR Newswire
PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and...
26 months ago
Nova Mentis Biotech Corp Signs Psilocybin Research Agreement with France-Based Physiogenex
Canada Newswire
CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that its...
44 months ago
An Acquisition, Rebrand and a Launch
Psychedelic Spotlight
This week in psychedelic business news: A major player begins manufacturing; another rebrands; and one of the biggest gets bigger.
27 months ago